Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study
Japanese Journal of Ophthalmology · 2026-07 · 70 (4) · 820-829
DOI: 10.1007/s10384-026-01340-5 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Japanese Journal of Ophthalmology, online erschienen am 10.04.2026. Verfasst von Hitoshi Ishikawa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Orthoptics and Visual Sciences, Kitasato University School of Allied Health Sciences, Kanagawa, Japan. Hauptthemen laut MEDLINE: Blepharoptosis, Oxymetazoline. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Santen.
Abstract (Originalsprache)
Purpose
To assess the 6-month efficacy and safety of oxymetazoline hydrochloride ophthalmic solution 0.1% (OMZ 0.1%) versus placebo for acquired blepharoptosis. Study design A phase 3, randomized, double-masked, parallel-group, multicenter study conducted in Japan.
Methods
Patients were randomized 1:1:1 to OMZ 0.1%, once daily (QD) or twice daily (BID), or placebo. Patients received OMZ 0.1% for 6 months. Patients in the placebo group were randomized after 3 months (Treatment Period 1) to OMZ 0.1%, either QD or BID, for the remaining 3 months (Treatment Period 2). The primary efficacy endpoint was the marginal reflex distance-1 (MRD-1) change from baseline to Day 14 (2 hours after the morning drop) with OMZ 0.1% QD or BID versus placebo. Adverse events and adverse drug reactions (ADRs) were recorded.
Results
Overall, baseline MRD-1 (standard deviation) of 336 patients analyzed (n=112 per group) was 1.31 (0.83) mm (Day 0). MRD-1 change from baseline to Day 14 (2 hours after the morning drop) was 1.09 (0.07), 0.93 (0.07), and 0.50 (0.07) mm, with OMZ 0.1% QD, BID, and placebo, respectively. There was a statistically significant difference in the least squares mean (standard error) MRD-1 change versus placebo with OMZ 0.1% QD (0.59 [0.10] mm; 95% CI 0.38, 0.79) and OMZ 0.1% BID (0.43 [0.10] mm; 95% CI 0.23, 0.64) (both p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Orthoptics and Visual Sciences, Kitasato University School of Allied Health Sciences, Kanagawa, Japan.
- Santen Pharmaceutical Co., Ltd, 4-20 Ofuka-cho, Kita-ku, Osaka, 530-8552, Japan. koji.oka@santen.com.
- Santen Pharmaceutical Co., Ltd, 4-20 Ofuka-cho, Kita-ku, Osaka, 530-8552, Japan.
Förderung
- Santen
Zitieren
APA
Ishikawa, H., Oka, K., & Inoue, H. (2026). Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study. Japanese Journal of Ophthalmology, 70(4), 820-829. https://doi.org/10.1007/s10384-026-01340-5
Vancouver
Ishikawa H, Oka K, Inoue H. Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study. Japanese Journal of Ophthalmology. 2026;70(4):820-829. doi:10.1007/s10384-026-01340-5
BibTeX
@article{Ishikawa2026,
author = {Ishikawa, Hitoshi and Oka, Koji and Inoue, Hiroshi},
title = {Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study},
journal = {Japanese Journal of Ophthalmology},
year = {2026},
volume = {70},
number = {4},
pages = {820--829},
doi = {10.1007/s10384-026-01340-5}
}
EUVIMED